Wegovy carries nearly five times Ozempic’s risk of a rare eye stroke that can blind you

Millions of people now inject semaglutide every week for weight loss or diabetes control, and a growing body of research is narrowing in on a rare but serious side effect tied to vision. A new analysis comparing the two best-known semaglutide brands finds the risk of a sudden, often irreversible eye stroke is substantially higher with one than the other, even though both drugs share the same active ingredient. The gap is large enough that researchers say it points to something beyond the medication’s chemistry alone.

What NAION Does to the Optic Nerve

The condition at the center of the research is nonarteritic anterior ischemic optic neuropathy, commonly shortened to NAION, sometimes described as an eye stroke. It occurs when blood flow to the optic nerve is reduced or cut off, starving the nerve fibers that carry visual signals to the brain. Unlike a stroke affecting a limb or speech, the damage from NAION is typically sudden, painless and permanent, and there is currently no surgical or medical treatment that reliably reverses the vision loss once it happens. That combination, sudden onset with no fix, is what has drawn attention to any medication that appears to raise its incidence even modestly.

How Wegovy and Ozempic’s Risk Compares

Researchers examined years of adverse event reports connected to semaglutide and found the safety signal for NAION was, according to the underlying study, almost five times higher for Wegovy than for Ozempic, despite the two products containing the exact same drug. That distinction matters because it rules out the simplest explanation, that semaglutide itself is uniquely dangerous to the optic nerve, and instead points toward something specific to how Wegovy is prescribed and dosed. The analysis also found the risk was roughly three times greater in men than in women, an additional wrinkle that dosage alone may not fully explain.

Why the Same Drug Produces Different Risk at Different Doses

Ozempic and Wegovy are approved for different purposes, type 2 diabetes management for the former and chronic weight management for the latter, and that difference in indication comes with a difference in typical maintenance dose. Wegovy is generally prescribed at higher doses than Ozempic’s standard diabetes regimen, and researchers studying the eye stroke signal have pointed to dosage as the most likely driver of the gap between the two products. A higher circulating dose of the same molecule could plausibly affect blood flow to the optic nerve more than a lower one, even though the underlying pharmacology is identical.

The Choice Facing Patients Already Injecting Semaglutide

NAION remains rare in absolute terms, and the vast majority of people taking either drug will never experience it. But the size of the relative risk difference between the two brands is large enough that clinicians are being encouraged to factor it into conversations with patients, particularly anyone who already has risk factors for reduced blood flow to the eye, such as high blood pressure, diabetes-related vascular damage or sleep apnea. Patients on Wegovy or Ozempic who notice any sudden change in vision, even in one eye, are advised to treat it as an emergency rather than something to monitor overnight, given how narrow the window is to preserve any remaining function once the optic nerve loses its blood supply. The research does not suggest either drug should be avoided outright; it suggests the decision between them, and the dose used within either one, is not simply interchangeable when it comes to this particular risk.

Why Adverse Event Reports Are a Signal, Not a Verdict

The comparison behind these numbers comes from adverse event reporting systems, large databases where doctors, patients and manufacturers submit reports of health problems that occur after starting a medication. That kind of data is useful for spotting a pattern worth investigating further, but it cannot on its own prove that semaglutide caused a given case of NAION rather than simply preceding it; people prescribed weight-loss or diabetes drugs often already carry cardiovascular risk factors that independently raise the odds of a vascular event like an eye stroke. Researchers account for that limitation by comparing rates across similar patient populations rather than looking at raw case counts, which is part of why the nearly fivefold difference between Wegovy and Ozempic is being treated as a meaningful signal rather than a coincidence of who happens to take which drug.

What Regulators and Drugmakers Have Said So Far

Findings like these typically prompt regulators to request additional safety data or update prescribing information rather than pull a drug from the market outright, particularly when the absolute risk remains low and the medication’s benefits for weight loss or blood sugar control are well established. Ophthalmologists studying NAION in semaglutide users have called for more targeted, prospective research that would track eye health in patients starting the drugs going forward, rather than relying solely on reports submitted after the fact. Until that more rigorous data exists, the adverse event signal stands as the best available evidence, and it is being incorporated into how doctors weigh the two brands against each other rather than treated as a reason to abandon the drug class entirely.

This article was produced with AI assistance and edited by Morning Overview staff.

More from Morning Overview